Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.29 -0.10 (-2.28%)
At close: Aug 20, 2026 · 1:53 PM UTC

Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Non Operating Income came in at $5.9 million in Q4 2025, up 16437.48% YoY from N/an in Q4 2024, and up 9243.26% on a QoQ basis from $62984.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Non Operating Income data on file, last reported at $5.9 million in Q4 2025.

  • Quarterly Non Operating Income rose 16437.48% year-over-year to $5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 5245.07% YoY) and the FY2025 annual result came in at $5.9 million, up 5245.07% from the prior year.
  • Non Operating Income climbed to $5.9 million in Q4 2025, from $62984.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.9 million in Q4 2025 to a low of -$38029.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Haleon 43.94 Bn 42.97 Bn - -
2 Teva Pharmaceutical Industries 43.08 Bn 39.43 Bn 2.15 Bn -224.00 Mn
3 Zoetis 31.54 Bn 29.87 Bn 1.05 Bn 5.00 Mn
4 Takeda Pharmaceutical 28.60 Bn 22.80 Bn 5.10 Bn -
5 United Therapeutics 22.12 Bn 19.46 Bn 683.80 Mn 41.90 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.50 Bn 15.11 Bn 935.80 Mn 10.70 Mn
8 Elanco Animal Health 11.69 Bn 11.16 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn - -
10 Apimeds Pharmaceuticals US 7.35 Mn 7.35 Mn - -13.89 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 5.88 Mn
Sep 30, 2025 62,984.00
Jun 30, 2025 1,711.00
Mar 31, 2025 -38,029.00
Dec 31, 2024 -36,020.00
Sep 30, 2024 -32,522.00
Jun 30, 2024 -21,606.00
Mar 31, 2024 -24,747.00